New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
08:49 EDTSQNMSequenom shares oversold at current levels, says Maxim
Maxim says Sequenom (SQNM) shares are oversold following the acquisition of competitor Verinata by Illumina (ILMN) and Verinata's partnership with PerkinElmer (PKI). The firm believes remains Sequenom remains well positioned for long-term growth and reiterates a Buy rating on the stock.
News For SQNM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
15:46 EDTSQNMPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 22, 2015
07:04 EDTSQNMSequenom and Cypher Genomics sign prenatal test development agreement
Subscribe for More Information
January 20, 2015
13:45 EDTSQNMIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information
January 12, 2015
15:40 EDTSQNMSequenom Q4 preliminary results disappointing, says Piper Jaffray
Subscribe for More Information
15:27 EDTSQNMSequenom sees FY15 accessioned tests above 200K
Subscribe for More Information
15:25 EDTSQNMSequenom sees Q4 revenue $37M, consensus $44.6M
Subscribe for More Information
15:21 EDTSQNMSequenom sees FY14 revenue $151M, consensus $160.7M
Sequenom reported FY14 preliminary revenue of $151M earlier in slides for its upcoming presentation at the JP Morgan Healthcare Conference. The company said in the slides that it had reduced its cash burn from $107M in FY13 to $37M in FY14 and ended FY14 with approximately $94M in cash. The company reported FY14 NIPT accessioned tests of 162. Sequenom shares are down 1% in afternoon trading after this morning's disclosure of the conference slides.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use